Session: SAT 224-247-Osteoporosis I
Poster Board SAT-233
Methods: Cumulative, prospective, registry study of men (mean age: 54.89 ± 6.31 years) with testosterone levels below 12.1 nmol/L. Their T scores were -2.99±0.4 (minimum -3.90, maximum -2.60). They received parenteral testosterone undecanoate 1000 mg/12 weeks following an initial 6-week interval for up to five years. After one year, 36 men were included in the registry, after two years, 32 men, after three years, 26 men, after four years, 10 men, after five years, 4 men. The declining numbers do not reflect drop-out rates but are a result of the registry design. New patients are consecutively entered once they have completed one year of treatment.
Results: Over the 5 year period there was a significant improvement of the T-score in these men. The mean T-score decreased from -2.99±0.4 (minimum: -3.90; maximum: -2.60) at baseline to -2.62±0.34 at 12 months, -2.29±0.32 at 24 months, -2.03±0.35 at 36 months, -1.75±0.2 at 48 months and -1.58±0.19 at 60 months without reaching a plateau. The improvement was progressive: each year of testosterone treatment led to a significant further improvement of the T-score (p<0.0001 vs baseline and vs previous year).
Conclusions: Normalizing of serum testosterone leads to an improvement of bone mineral density and this improvement is progressive throughout the time period of testosterone administration.
Disclosure: AH: Speaker, Bayer Pharma AG, Speaker, Takeda. AMT: Investigator, Bayer Pharma AG. GD: , Bayer Pharma AG. FS: Employee, Bayer Pharma AG. Nothing to Disclose: LJG, UM
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters